Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Learning objectives
- Flowing blood - normal haemostasis
- Initiation of coagulation
- FVIII massively amplifies production of FXa
- Amplification of coagulation
- Life cycle of factor VIII
- FVIII activation
- Clinical significance of FVIII deficiency (1)
- What is the defect in an haemophilia-A patient?
- FV and FVIII gene structure
- Haemophilia-A and the FVIII gene
- Types of mutation
- FVIII gene inversions
- Inversions: basic mechanism
- Haemophilia-A mutations, 2006
- Relationship of mutation type to disease severity
- The haemophilia-A mutation database
- "Molecular pathology"
- Loss of protein or loss of function?
- How do small mutations cause haemophilia-A?
- What structures are available? (1996)
- Factor VIII homologous proteins
- Evolution of A-domain-containing proteins
- Crystal structure of ceruloplasmin (Cp), 1996
- FVIII-A domain homology model based on Cp
- Crystal structure of FVIII C2 domain solved, 1999
- All-domain FVIII model (electron microspcopy)
- Interpreting haemophilic mutations by FVIII model
- FVIII function is to complex with FIXa
- Clinical significance of FVIII deficiency (2)
- Other gene defects result in FVIII reduction
- Factors VIII and V B-domains
- Trafficking of FVIII or FV from the ER
- Effect of mutations in LMAN1 or MCFD2
- References
Topics Covered
- Normal blood coagulation
- What is haemophilia A?
- Different types of factor VIII gene mutations
- Loss of protein or loss of function
- Structural interpretation of protein dysfunction
- Other rare causes of FVIII deficiency
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Kemball-Cook, G. (2016, May 31). Factor VIII and haemophilia A [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 26, 2024, from https://doi.org/10.69645/TXFI1632.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Geoffrey Kemball-Cook has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Haematology
Transcript
Please wait while the transcript is being prepared...
0:00
My
name is Geoff Kemball-Cook
and I work in the hemostasis and
thrombosis group of the Clinical
Sciences Center in London.
My talk is on Factor
VIII and hemophilia A.
0:10
I'd like to touch
on three main areas.
First is to review the normal
coagulant function of factor VIII.
The second is to move on to describe
the molecular pathology that we
find in patients with
hemophilia A. And lastly,
to briefly mention a
rare bleeding disorder,
combined factor V-
factor VIII deficiency.
0:31
So a brief review of factor
VIII function in coagulation.
The cartoon in this slide shows
blood flowing from left to right
in the upper part within a vessel.
This is demarcated by the
endothelial cell layer, marked
as ECs in the slide, which
presents an anticoagulant surface
to flowing blood, including the
soluble coagulation factors shown.
For example, factor
VIII, VII, X, et cetera.
And the various blood cells,
which are also immersed in plasma.
Outside the endothelial cell
layer, in the vascular tissue,
are found cells
bearing tissue factor,
or TF, which is a potent
initiator of coagulation.
1:10
In the event to vascular damage,
blood flows out under pressure
through a breach in
the endothelial cell
layer and contacts the
extravascular tissues.
In particular, coagulation
factor VII forms a tight complex
with tissue factor,
and this constitutes
the initiates of coagulation.
1:29
What part does FVIII play in
amplifying this initial stimulus?
Well, tissue factor VIIa complex is
capable of producing small amounts
of factor Xa and factor IXa, which
are activated serine proteases,
from their zymogen forms.
However, the levels of factor
Xa produced by this direct route
are inadequate to produce the
amount of thrombin needed to produce
a solid clot from
fibrinogen. Hence, factor
VIII and the related
molecule, factor V,
are activated by trace
amounts of thrombin
to their active cofactor forms,
factor VIIIa and factor Va.
In the case of factor VIIIa,
this assembles with trace amounts
of factor IXa to
produce an extremely
potent complex for increasing the
rate of cleavage of factor X to Xa.
This enormously increased
amount of factor Xa
is then able to produce the
large amounts of thrombin which
are necessary to make a solid clot.